Anti-Human APP/Protease Nexin II Reference Antibody (Dalidnetug, RUO) (HY235286)

Name: Anti-Human APP/Protease Nexin II Reference Antibody (Dalidnetug, RUO)
Brand: abinScience
SKU: HY235286
Price: 176 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HY235286
Description	dalidnetug (HY235286) is a research-grade recombinant antibody targeting APP/Amyloid beta. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG1, Kappa
Species	Human
Clonality	Monoclonal
Target	APP/Amyloid beta
Endotoxin level	< 10 EU/mg
Purity	>95% as determined by SDS-PAGE.
Accession	P05067
Form	Liquid
Reconstitution	Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping	In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	2991369-43-6
Background	Amyloid-beta precursor protein (APP/Amyloid beta) is a ~86 kDa protein. Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. APP is the therapeutic target of lecanemab (Leqembi). 1. Baumkötter, F. et al. (2014) The Journal of neuroscience : the official journal of the Society for Neuroscience 34, 11159-72. PMID: 25122912 2. Satpute-Krishnan, P. et al. (2006) Proceedings of the National Academy of Sciences of the United States of America 103, 16532-7. PMID: 17062754 3. Seamster, PE. et al. (2012) Physical biology 9, 055005. PMID: 23011729
Note	For research use only. Not suitable for clinical or therapeutic use.